Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer [0.03%]
抗α3Gal免疫球蛋白E检测在头颈部癌症西妥昔单抗介导的过敏反应中的临床应用价值
Y Pointreau,C Freneaux,T Bejan-Angoulvant et al.
Y Pointreau et al.
Background: Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed...
The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study [0.03%]
MELimmune评分--晚期黑色素瘤和抗PD-1单药治疗的总体生存预后因素--多中心，回顾性队列研究
S Lobo-Martins,D Martins-Branco,P M Semedo et al.
S Lobo-Martins et al.
Background: Immunotherapy has revolutionized advanced melanoma treatment. Several prognostic factors have been studied to predict survival in this setting. We aimed to develop a prognostic score. ...
Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis [0.03%]
II/III期黑色素瘤中通过无复发生存期的改善来预测总生存获益的挑战与机遇：相关性Meta分析
L Leung,J M Kirkwood,S Srinivasan et al.
L Leung et al.
Background: We evaluated the association between treatment effects on recurrence-free survival (RFS) and overall survival (OS) in randomized controlled trials (RCTs) studying resected stage II/III melanoma. ...
Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics [0.03%]
免疫检查点抑制剂增强瘤内治疗：多模式治疗理念的转变
B E Nelson,A Naing,S Fu et al.
B E Nelson et al.
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a cri...
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers [0.03%]
基于新抗原的肿瘤浸润性淋巴细胞(TIL)治疗晚期实体瘤或免疫检查点抑制剂耐药实体瘤的临床前数据和I期临床试验设计
J Palomero,V Galvao,I Creus et al.
J Palomero et al.
Background: Adoptive cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs) can mediate objective tumor regression in 28%-49% of metastatic melanoma patients. However, the efficacy of TIL therapy in ...
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma [0.03%]
肿瘤浸润淋巴细胞免疫疗法联合纳武单抗治疗晚期黑色素瘤患者的临床研究
D König,B Kasenda,M Sandholzer et al.
D König et al.
Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not ...
W K Lim,N G Iyer
W K Lim
γδ T cells represent an 'unconventional' class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles of γδ...
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy [0.03%]
作为癌症治疗的微型药房对嵌合抗原受体(CAR)T细胞进行装甲防护
C Carcopino,E Erdogan,M Henrich et al.
C Carcopino et al.
Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer. However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression wit...
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy [0.03%]
接受免疫治疗的患者的AXL和/或MITF黑色素瘤亚群的变化
M Willemsen,J Bulgarelli,S K Chauhan et al.
M Willemsen et al.
Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the 'mixed responses' frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resist...
Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications [0.03%]
分析效应细胞的功能异质性以增强过继性细胞疗法的效果
A C Kiel Rasmussen,T M Hulen,D L Petersen et al.
A C Kiel Rasmussen et al.
Cellular effector function assays traditionally rely on bulk cell populations that mask complex heterogeneity and rare subpopulations. The Xdrop® droplet technology facilitates high-throughput compartmentalization of viable single cells or...